The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J05 | Antivirals for systemic use | |
| 3 | J05A | Direct acting antivirals | |
| 4 | J05AR | Antivirals for treatment of HIV infections, combinations | |
| 5 | J05AR25 | Lamivudine and dolutegravir |
| Active Ingredient | Description | |
|---|---|---|
| Lamivudine and Dolutegravir |
Lamivudine and dolutegravir combination is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents. Dolutegravir inhibits HIV integrase and lamivudine, via its active metabolite 5'-triphosphates (TP) (an analogue for cytidine), inhibits reverse transcriptase of HIV-1 and HIV-2. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DOVATO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
